ABBOTT LABORATORIES

ABT - CIK 0000001800

Market cap$154.72 B

Rank#96

SEC filings1,001

ABBOTT LABORATORIES trades as ABT and has a market capitalization of $154.72 B, making it the #96 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $44.33B, up 5.7% from the prior year and net income of $6.52B. This page tracks ABBOTT LABORATORIES through 1,001 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$44.33BFY 2025

Net income (latest FY)$6.52BFY 2025

Operating cash flow (latest FY)$9.57BFY 2025

Total assets (latest FY)$86.71BFY 2025

Net margin14.7%latest FY

Financial performance

Over the last 9 fiscal years ABBOTT LABORATORIES's revenue grew from $20.85B to $44.33B, a compound annual growth rate of 8.7%. Net profit margin expanded from 6.7% to 14.7% over the same period - every figure below comes from the company's audited annual filings.

ABT annual revenueView details

Key statistics

Market cap: $154.72 B
Share price (derived)market cap / shares outstanding: $88.83
P/E ratio (trailing FY): 23.7
EPS (diluted)FY 2025: $3.72
Shares outstandingas of 2026-03-31: 1.74B
Total equityas of 2026-03-31: $52.06B
Return on equity: 12.5%
Long-term debtas of 2026-03-31: $29.64B

Latest filings

Filing	Type	Filed
Insider sale notice	144	2026-05-15
SCHEDULE 13G	-	2026-04-29
Insider trade	4	2026-04-29
Quarterly report	10-Q	2026-04-29
Insider trade	4	2026-04-28
Insider trade	4	2026-04-28
Insider trade	4	2026-04-28
Insider trade	4	2026-04-28

Browse the full filing history (1,001 filings)

Recent press releases

Investors | Stocks and Financial Information | Abbott U.S.
Archive of Abbott investor newsletters, highlighting the latest in Abbott updates for the savvy investor.
Q1 progress positions Abbott for accelerating growth in 2026
Sales for the quarter totaled $11.2 billion, a 3.7% increase on a comparable basis1 (7.8% reported), with growth led by Medical Devices and ...
Abbott Delivers Top-Tier Q1 Sales and EPS Growth
Abbott reported first-quarter 2025 results, delivering top-tier sales and EPS growth. The company's diversified business model is helping it ...
Abbott's Q4 Earnings Sustain Momentum Into 2024
Reported sales decreased 8.1% due to the anticipated decline in COVID-19 testing-related revenue. Full-year adjusted diluted EPS was $4.44, ...

Similar companies

The largest companies sharing ABBOTT LABORATORIES's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T ABT vs LLY

JNJJohnson & Johnson$573.98 B ABT vs JNJ

ABBVAbbVie Inc.$399.47 B ABT vs ABBV

MRKMerck & Co., Inc.$293.16 B ABT vs MRK

AZNAstraZeneca PLC$286.27 B ABT vs AZN

Frequently asked questions

What is ABBOTT LABORATORIES's market cap?

ABBOTT LABORATORIES (ABT) has a market capitalization of $154.72 B as of 2026-06-10, ranking #96 among US-listed companies.

How much revenue does ABBOTT LABORATORIES make?

ABBOTT LABORATORIES reported revenue of $44.33B for fiscal year 2025, an increase of 5.7% year over year.

Is ABBOTT LABORATORIES profitable?

Yes. ABBOTT LABORATORIES reported net income of $6.52B in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.